SAN ANTONIO, Feb. 3 /PRNewswire/ -- BioComp Pharma, Inc. launched Tinidazole 500, the first generic version of the FDA-approved drug Tindamax(R). Tindamax(R) is the only oral antimicrobial drug approved by the FDA for the treatment of both trichomoniasis (trich) and bacterial vaginosis (BV). BioComp Pharma will begin shipping the generic version of Tindamax(R) in February 2009.
Generic drugs have the same active ingredients and efficacy as branded drugs but, on average, cost 30 to 80 percent less.(1) In 2007, the average price of a generic prescription drug was $34.34, while the average price of a brand-name prescription drug was $119.41, according to the National Association of Chain Drug Stores.(2)
With an estimated 7.4 million new cases of trich in men and women each year,(3) it is the most common curable sexually transmitted disease in young, sexually-active women in the United States.(4) BV affects almost one-third of women (29.2 percent) in the United States(5) and is the most common vaginal infection in women of childbearing age.(6)
Tindamax(R) is administered in one gram (two 500 mg tablets, once daily for five days) or two grams (four 500 mg tablets, once daily for two days) for the treatment of BV, compared to the twice daily, seven day oral dosing of metronidazole, the current standard of care. Tindamax(R) is administered as two grams (four 500 mg tablets for one day) for the treatment of trich. The drug's formulation helps minimize treatment time by allowing for targeted dosing and a shorter course of therapy.
About BioComp Pharma, Inc.
BioComp Pharma, Inc. is a wholly-owned subsidiary of Mission Pharmacal Company, a privately-held pharmaceutical company based in San Antonio, Texas. Established in 2008, BioComp Pharma, Inc. distributes biocomparable drug products, which are less expensive than their prescription equivalent products. For more information on BioComp Pharma, visit www.biocomppharma.com.
Tindamax(R) is a second-generation 5-nitroimidazole compound and is indicated in the United States for the treatment of bacterial vaginosis, trichomoniasis, the intestinal infections giardiasis and intestinal amebiasis and amebic liver abscess.
Media Contact: Cohn & Wolfe Ms. Ami Shah (212) 537-8048 firstname.lastname@example.org
(1) Saving Money on Prescription Drugs. U.S. Food and Drug Administration. Accessed at:http://www.fda.gov/fdac/features/2005/505_save.html#generic. Last accessed: January 25, 2009
(2) Industry facts-at-a-glance. National Association of Chain Drug Stores. Accessed at: http://www.nacds.org/wmspage.cfm?parm1=507. Last accessed: January 25, 2009.
(3) Trichomoniasis - CDC Fact Sheet. Centers for Disease Control. Accessed at: http://www.cdc.gov/STD/Trichomonas/STDFact-Trichomoniasis.htm. Last accessed: January 24, 2009.
(4) Trichomoniasis - CDC Fact Sheet. Centers for Disease Control. Accessed at: http://www.cdc.gov/STD/Trichomonas/STDFact-Trichomoniasis.htm. Last accessed: January 24, 2009.
(5) J.E. Allsworth, J.F. Peipert. "Prevalence of Bacterial Vaginosis: 2001-2004 National Health and Nutrition Examination Survey Data," Obstetrics and Gynecology 2007; 109(1): 114-120.
(6) Bacterial Vaginosis - CDC Fact Sheet. Centers for Disease Control. Accessed at: http://www.cdc.gov/STD/BV/STDFact-Bacterial-Vaginosis.htm . Last accessed: 2009.
|SOURCE BioComp Pharma, Inc.|
Copyright©2009 PR Newswire.
All rights reserved